Are You Aware That In The AFCAPS/TexCAPS Trial OVERALL MORTALITY Was INCREASED !


Question:

Are You Aware That In The AFCAPS/TexCAPS Trial OVERALL MORTALITY Was INCREASED By 4 %?

ACTUAL DATA for AFCAPS/TexCAPS Trial

Lovastatin 20-40 mg Double Blind 5.2 years


Healthy males and females with normal cholesterol.


Number of participants Drug/Control 3304/3301



CHD deaths 11/15

Total deaths 80/77

Relative risk for CHD Mortality -27%

Relative Risk for Total Mortality +3.9

In the AFCAPS /TexCAPS Trial lovastatin reduced CHD mortality bey a statistically insignificant twnety seven percent but OVERALL MORTALITY was INCREASED by almost four percent.

Are you aware of this?


THIS IS THE ACTUAL DATA HARMONY

NO MORE NONSENSE FROM YOU WITH YOUR AHA PROPAGANDA ABSTRACTS AND REVIEWS WRITTEN BY LIPID HYPOTHESIS PROPONENTS

The people on here WILL NOT BE FOOLED and SCAMMED by YOU as long as RAZWELL is here
They can see the ACTUAL DATA THEMSELVES


Answers:

You failed yet again to properly cite you source. How hard is it to include the article title? AFCAPS /TexCAPS was in the title of 23 different articles.

The information I found supported the use of statins. You are failing to consider the big picture. Since the study population was at low risk of CHD mortality to begin with, decreasing CHD deaths did not impact overall mortality as much as it would in a population at high risk.

"Treatment with lovastatin (20 to 40 mg/d) resulted in mean on-treatment LDL-C values of 2.96 mmol/L (114.6 mg/dL) and HDL-C 1.02 mmol/L (39.3 mg/dL) at year 1, as a result of a mean reduction in LDL-C of 25% and a mean increase in HDL-C of 6%.

Lovastatin-mediated changes in these lipids were associated with a 37% decrease in AMCEs (defined as fatal or nonfatal myocardial infarction, unstable angina, or sudden cardiac death).5 These results, taken in aggregate with other large-scale clinical trials of HMG-CoA reductase inhibitors, demonstrate the benefit of reducing LDL-C and increasing HDL-C across a broad range of baseline cholesterol values...

The lack of a statistically significant association with the logistic regression models between baseline TC or LDL-C, as individual analyses, and CHD risk in this cohort may be explained in several ways. First, these participants would not have been considered at high risk for a coronary event based solely on the TC or LDL-C concentration. In fact, under current US guidelines, a fasting lipid profile would not have been recommended for 2137 (32%) of the AFCAPS/TexCAPS cohort with TC <6.21 mmol/L (240 mg/dL)."




The consumer health information on answer-health.com is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions.
The answer content post by the user, if contains the copyright content please contact us, we will immediately remove it.
Copyright © 2007-2011 answer-health.com -   Terms of Use -   Contact us

Health Categories